ESMO Asia Congress 2019: ESMO Colloquia

The ESMO Colloquia are innovative sessions within the Congress programme that bring together top experts to discuss evolving areas of interest to the oncology community.

The Colloquia are organised by ESMO and supported by the industry in a unique collaboration making them the perfect complement to the scientific and education programme of the Congress.

View the complete ESMO Asia Congress 2019 programme online

Friday, 22 November 2019

ESMO Colloquium: Biomarker-driven treatment decision in metastatic NSCLC

Biomarker-Driven-Treatment-Decision-in-Metastatic-NSCLC-thumb

Hall 407, 12:45 – 14:15
This educational activity is provided by ESMO and supported by Lilly Oncology.
View the ESMO Colloquium details

Learning Objectives

  • Review the optimal immunotherapy options for NSCLC in first-line
  • Updated knowledge on treatment of EGFR mutant NSCLC as single agent or in combination
  • Optimise the use of biomarkers for patient selection and management
  • Integrate new data within the most recent ESMO Guidelines

Sunday, 24 November 2019

ESMO Colloquium: Liquid biopsy in the management of solid tumours

Liquid-Biopsy-in-the-Management-of-Solid-Tumours-thumb

Room 311, 11:00 - 12:30
This educational activity is provided by ESMO and supported by Guardant Health.
View the ESMO Colloquium details

Learning Objectives

  • Review the source material and the available technological aspects
  • Optimise the use of biomarkers from liquid biopsies at diagnosis for patient selection and management
  • Assess the role of repeated liquid biopsies at recurrence; understand potential experimental uses of liquid biopsy for assessment of treatment effect
  • Integrate new data within the most recent ESMO Guidelines and ESCAT
  • Provide an update on the use of liquid biopsies by medical oncologists in lung, breast, and colorectal cancers

Sunday, 24 November 2019

ESMO Colloquium: State of the art management of mCPRC

State-of-the-Art-Management-of-mCPRC-thumb

Summit 2, 11:00 - 12:30
This educational activity is provided by ESMO and supported by Astellas.
View the ESMO Colloquium details

Learning Objectives

  • How to best characterize metastatic castration resistant prostate cancer (mCRPC)
  • Understand the management of mCRPC with the new therapeutic options and related biomarkers
  • To elucidate the optimal treatment sequence in the management of mCRPC
  • To explore the role of immunotherapy in the management of mCRPC